Douglas I. Lin

5.0k total citations · 1 hit paper
112 papers, 2.6k citations indexed

About

Douglas I. Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Douglas I. Lin has authored 112 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 36 papers in Cancer Research. Recurrent topics in Douglas I. Lin's work include Cancer Genomics and Diagnostics (34 papers), Ovarian cancer diagnosis and treatment (16 papers) and Genetic factors in colorectal cancer (15 papers). Douglas I. Lin is often cited by papers focused on Cancer Genomics and Diagnostics (34 papers), Ovarian cancer diagnosis and treatment (16 papers) and Genetic factors in colorectal cancer (15 papers). Douglas I. Lin collaborates with scholars based in United States, Italy and Switzerland. Douglas I. Lin's co-authors include J. Alan Diehl, Massimo Loda, Sabina Signoretti, Levi A. Garraway, David Waltregny, James R. Dilks, Anil K. Rustgi, Jeffrey S. Ross, Rodolfo Montironi and Annie Yang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Douglas I. Lin

103 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

2023 75 citations Smruthy Sivakumar, Jay A. Moore et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Douglas I. Lin

Since Specialization

Citations

This map shows the geographic impact of Douglas I. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas I. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas I. Lin more than expected).

Fields of papers citing papers by Douglas I. Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas I. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas I. Lin. The network helps show where Douglas I. Lin may publish in the future.

Co-authorship network of co-authors of Douglas I. Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas I. Lin. A scholar is included among the top collaborators of Douglas I. Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas I. Lin. Douglas I. Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer 2025 ·International Journal of Gynecological Cancer ·Brian M. Slomovitz, Natalie Danziger, Júlia C.F. Quintanilha, Andrew D. Kelly, Gerald Li, Vivek Podder, Douglas I. Lin, Ryon P. Graf, Julia A. Elvin, Thomas J. Herzog	1
2	Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study 2025 ·ESMO Open ·(unknown), (unknown), Dean C. Pavlick, S. Lindsey Davis, Christopher H. Lieu, (unknown), Laura Graham, Philippe E. Spiess, Ruichao Li, Ashish M. Kamat, Petros Grivas, (unknown), Gennady Bratslavsky, (unknown), Kum Thong Wong, Douglas I. Lin, Andrea Necchi, Jeffrey S. Ross, Elaine T. Lam	0
3	Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations 2024 ·International Journal of Gynecological Pathology ·(unknown), Austin McHenry, (unknown), Alessandro D. Santin, Elena Ratner, Douglas I. Lin, Julia A. Elvin, Pei Hui, Natália Buza	3
4	Real-world pan-tumor comprehensive genomic profiling sample adequacy and success rates in tissue and liquid specimens 2024 ·The Oncologist ·Douglas I. Lin, Lincoln W. Pasquina, (unknown), Julia A. Elvin, Richard S.P. Huang	0
5	Urachal (U) and non-urachal (NU) adenocarcinomas (adenoCA) of the bladder: A comparative comprehensive genomic profiling (CGP) study. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Joseph M Jacob, Gennady Bratslavsky, Liang Cheng, Petros Grivas, Ashish M. Kamat, Philippe E. Spiess, Dean C. Pavlick, Douglas I. Lin, Jeffrey S. Ross, Andrea Necchi	3
6	Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness 2023 ·JCO Precision Oncology ·Júlia C.F. Quintanilha, (unknown), Ryon P. Graf, Gerald Li, Rachel B. Keller, Douglas I. Lin, Jeffrey S. Ross, Richard S.P. Huang, Alexa B. Schrock, Geoffrey R. Oxnard, Sakti Chakrabarti, Amit Mahipal	31
7	Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation breakdown → 2023 ·Cancer Discovery ·Smruthy Sivakumar, Jay A. Moore, Meagan Montesion, Radwa Sharaf, Douglas I. Lin, Caterina I. Colón, (unknown), Ericka M. Ebot, Justin Y. Newberg, (unknown), (unknown), Quintin Pan, Afshin Dowlati, Garrett M. Frampton, Julien Sage, Christine M. Lovly	75
8	Genomic landscape of 891 RET fusions detected across diverse solid tumor types 2023 ·npj Precision Oncology ·Vamsi Parimi, Khaled Tolba, Natalie Danziger, (unknown), (unknown), Douglas I. Lin, Matthew Hiemenz, Alexa B. Schrock, Jeffrey S. Ross, Geoffrey R. Oxnard, Richard S.P. Huang	34
9	Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC). 2023 ·Journal of Clinical Oncology ·Haley Ellis, Samuel J. Klempner, (unknown), Parvathi A. Myer, Douglas I. Lin, Nicole C. Panarelli, Virginia Fisher, Gerald Li, Richard S.P. Huang, Jeffrey S. Ross, Geoffrey R. Oxnard, Ryon P. Graf	2
10	Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry 2023 ·The Oncologist ·Taylor Peak, Philippe E. Spiess, Roger Li, Petros Grivas, Andrea Necchi, Dean C. Pavlick, Richard S.P. Huang, Douglas I. Lin, Natalie Danziger, Joseph M Jacob, Gennady Bratslavsky, Jeffrey S. Ross	1
11	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden 2023 ·JAMA Network Open ·Júlia C.F. Quintanilha, Ryon P. Graf, Virginia Fisher, Geoffrey R. Oxnard, Haley Ellis, Nicole C. Panarelli, Douglas I. Lin, Gerald Li, Richard S.P. Huang, Jeffrey S. Ross, Parvathi A. Myer, Samuel J. Klempner	26
12	Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma 2022 ·Modern Pathology ·(unknown), Tyler Janovitz, (unknown), Douglas A. Mata, Meagan Montesion, Jessica Lee, Russell W. Madison, Alexa B. Schrock, Hanna Tukachinsky, Justin Allen, Rachel Erlich, Matthew Hiemenz, Richard S.P. Huang, Julia A. Elvin, Jo‐Anne Vergilio, Douglas I. Lin, Jeffrey S. Ross, Geoffrey R. Oxnard, Brennan Decker	2
13	CDKN2C -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53 / RB1 –Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion 2020 ·JCO Precision Oncology ·Erik A. Williams, Radwa Sharaf, Brennan Decker, (unknown), (unknown), Meagan Montesion, Ethan S. Sokol, Dean C. Pavlick, (unknown), Kevin Jon Williams, Jeffrey M. Venstrom, Brian M. Alexander, Jeffrey S. Ross, Lee A. Albacker, Douglas I. Lin, Shakti Ramkissoon, Julia A. Elvin	10
14	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions 2020 ·British Journal of Urology ·Russell W. Madison, Sumati Gupta, Yasir Y. Elamin, Douglas I. Lin, Sumanta K. Pal, Andrea Necchi, Vincent A. Miller, Jeffrey S. Ross, Jon Chung, Brian M. Alexander, Alexa B. Schrock, John V. Heymach, Prasanth Reddy, Siraj M. Ali	11
15	Automated clear cell renal carcinoma grade classification with prognostic significance 2019 ·PLoS ONE ·Katherine Tian, (unknown), Douglas I. Lin, Mitko Veta, Michael E. Pyle, Humayun Irshad, Yujing J. Heng	41
16	Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas 2018 ·PLoS ONE ·Jia Xu, Douglas I. Lin	28
17	Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma 2015 ·Oncology Letters ·Douglas I. Lin	6
18	Architectural Versus Nuclear Atypia-defined FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma (EEC) 2014 ·International Journal of Gynecological Pathology ·(unknown), Douglas I. Lin, Pamela Stone, Marisa R. Nucci, Charles M. Quick	1
19	Mutations in Fbx4 Inhibit Dimerization of the SCFFbx4 Ligase and Contribute to Cyclin D1 Overexpression in Human Cancer 2008 ·Cancer Cell ·Olena Barbash, (unknown), Douglas I. Lin, Xiangmei Chen, Yang Ke, Hiroshi Nakagawa, Fengmin Lu, Anil K. Rustgi, J. Alan Diehl	118
20	Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex 2006 ·Molecular Cell ·Douglas I. Lin, Olena Barbash, Suresh Kumar, Jason D. Weber, J. Wade Harper, Andres J. Klein–Szanto, Anil K. Rustgi, Serge Y. Fuchs, J. Alan Diehl	299

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact